3.0
Mar 9, 2017
Anonymous employee
Current employee, more than 5 years
Tucson, AZ
Recommend
CEO approval
Business Outlook
Pros
Opko purchased BioReference in Aug 2015. Until then BioReference had operated in a small company mode even though their revenue was over 800 million per year and they grew 15% to 25% per year. After the purchase more corporate procedures and processes were incorporated as expected (and often needed) but the corporate culture changed.
Cons
Since the turnover of CEO Marc Grodman approximately a year ago the company culture has significantly changed. Implementation of SAP, and many other systems have decreased corporate productivity. There has been significant upper management turnover, especially in the genetics area.